PMID: 9447444Jan 1, 1997Paper

Discriminant analysis of brain imaging data identifies subjects with early Alzheimer's disease

International Psychogeriatrics
S I Rapoport

Abstract

In vivo functional brain imaging provides an opportunity to quantify and localize functional deficits associated with Alzheimer's disease (AD), in relation to dementia severity and heterogeneous cognitive profiles. Such imaging also provides a basis for distinguishing AD from other causes of dementia and for making an early diagnosis of disease. One imaging modality that can elucidate AD is positron emission tomography (PET), which is used to measure regional cerebral metabolic rates for glucose (rCMRglc) and regional cerebral blood flow (rCBF). Resting-state measurements with PET, when related to cognitive profiles in longitudinal studies, indicate that specific cognitive defects are preceded and predicted by reductions in rCMRglc in regions subserving the cognitive functions tested. Metabolic reductions and right/left metabolic asymmetries can be used to convert a "possible" to a "probable" diagnosis of AD by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. Furthermore, discriminant analyses of PET metabolic patterns can identify patients at risk for AD with mild memory deficits as having probable AD. In the future, sti...Continue Reading

Citations

Oct 6, 2000·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·T DierksA Nordberg
Jul 10, 2003·Lancet Neurology·Stanley I Rapoport
Mar 4, 2003·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Brandy MatthewsP David Mozley
Oct 19, 2000·Journal of the American Geriatrics Society·C BeckG W Small

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Related Papers

Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)
R A Armstrong, A B Syed
Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging
Laura L Boles PontoSusan K Schultz
The Journal of Neuropsychiatry and Clinical Neurosciences
Xiying ChenSusan K Schultz
© 2021 Meta ULC. All rights reserved